These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 37302319)

  • 1. The great potential of flavonoids as candidate drugs for NAFLD.
    Li L; Qin Y; Xin X; Wang S; Liu Z; Feng X
    Biomed Pharmacother; 2023 Aug; 164():114991. PubMed ID: 37302319
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The potential of flavonoids in the treatment of non-alcoholic fatty liver disease.
    Van De Wier B; Koek GH; Bast A; Haenen GR
    Crit Rev Food Sci Nutr; 2017 Mar; 57(4):834-855. PubMed ID: 25897647
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Flavonoids and Related Compounds in Non-Alcoholic Fatty Liver Disease Therapy.
    Pisonero-Vaquero S; González-Gallego J; Sánchez-Campos S; García-Mediavilla MV
    Curr Med Chem; 2015; 22(25):2991-3012. PubMed ID: 26242257
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatoprotective Effect of Loquat Leaf Flavonoids in PM
    Jian T; Ding X; Wu Y; Ren B; Li W; Lv H; Chen J
    Int J Mol Sci; 2018 Oct; 19(10):. PubMed ID: 30275422
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MicroRNAs in the Pathogenesis of Nonalcoholic Fatty Liver Disease.
    Fang Z; Dou G; Wang L
    Int J Biol Sci; 2021; 17(7):1851-1863. PubMed ID: 33994867
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Induction of autophagy via the PI3K/Akt/mTOR signaling pathway by Pueraria flavonoids improves non-alcoholic fatty liver disease in obese mice.
    Sun C; Zhang J; Hou J; Hui M; Qi H; Lei T; Zhang X; Zhao L; Du H
    Biomed Pharmacother; 2023 Jan; 157():114005. PubMed ID: 36384052
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An overview of ferroptosis in non-alcoholic fatty liver disease.
    Wang S; Liu Z; Geng J; Li L; Feng X
    Biomed Pharmacother; 2022 Sep; 153():113374. PubMed ID: 35834990
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Roles of the peroxisome proliferator-activated receptors (PPARs) in the pathogenesis of nonalcoholic fatty liver disease (NAFLD).
    Qiu YY; Zhang J; Zeng FY; Zhu YZ
    Pharmacol Res; 2023 Jun; 192():106786. PubMed ID: 37146924
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Endoplasmic reticulum stress in nonalcoholic (metabolic associated) fatty liver disease (NAFLD/MAFLD).
    Flessa CM; Kyrou I; Nasiri-Ansari N; Kaltsas G; Kassi E; Randeva HS
    J Cell Biochem; 2022 Oct; 123(10):1585-1606. PubMed ID: 35490371
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The miR-23-27-24 cluster: an emerging target in NAFLD pathogenesis.
    Ru L; Wang XM; Niu JQ
    Acta Pharmacol Sin; 2022 May; 43(5):1167-1179. PubMed ID: 34893685
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A new perspective on NAFLD: Focusing on lipid droplets.
    Scorletti E; Carr RM
    J Hepatol; 2022 Apr; 76(4):934-945. PubMed ID: 34793866
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Non-alcoholic fatty liver disease.
    Powell EE; Wong VW; Rinella M
    Lancet; 2021 Jun; 397(10290):2212-2224. PubMed ID: 33894145
    [TBL] [Abstract][Full Text] [Related]  

  • 13. p53 as a double-edged sword in the progression of non-alcoholic fatty liver disease.
    Yan Z; Miao X; Zhang B; Xie J
    Life Sci; 2018 Dec; 215():64-72. PubMed ID: 30473026
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Advances in the Diagnosis and Treatment of Non-Alcoholic Fatty Liver Disease.
    Yin X; Guo X; Liu Z; Wang J
    Int J Mol Sci; 2023 Feb; 24(3):. PubMed ID: 36769165
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Non-alcoholic fatty liver disease and dyslipidemia: An update.
    Katsiki N; Mikhailidis DP; Mantzoros CS
    Metabolism; 2016 Aug; 65(8):1109-23. PubMed ID: 27237577
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Herbal medicines and nonalcoholic fatty liver disease.
    Yao H; Qiao YJ; Zhao YL; Tao XF; Xu LN; Yin LH; Qi Y; Peng JY
    World J Gastroenterol; 2016 Aug; 22(30):6890-905. PubMed ID: 27570425
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lipidomic biomarkers and mechanisms of lipotoxicity in non-alcoholic fatty liver disease.
    Svegliati-Baroni G; Pierantonelli I; Torquato P; Marinelli R; Ferreri C; Chatgilialoglu C; Bartolini D; Galli F
    Free Radic Biol Med; 2019 Nov; 144():293-309. PubMed ID: 31152791
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune mechanisms linking metabolic injury to inflammation and fibrosis in fatty liver disease - novel insights into cellular communication circuits.
    Peiseler M; Schwabe R; Hampe J; Kubes P; Heikenwälder M; Tacke F
    J Hepatol; 2022 Oct; 77(4):1136-1160. PubMed ID: 35750137
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Natural products in non-alcoholic fatty liver disease (NAFLD): Novel lead discovery for drug development.
    Wang L; Yan Y; Wu L; Peng J
    Pharmacol Res; 2023 Oct; 196():106925. PubMed ID: 37714392
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Deranged hepatocyte intracellular Ca
    Ali ES; Rychkov GY; Barritt GJ
    Cell Calcium; 2019 Sep; 82():102057. PubMed ID: 31401389
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.